Streetbeat News

Regulatory

BA

The Boeing 737 Max is facing renewed public scrutiny and trust issues, as passengers, including a former Boeing employee and a marketing professional, are choosing to boycott the aircraft due to safety concerns. This follows a reputation-damaging incident with Alaska Airlines and concerns raised by a Netflix documentary about Boeing's working environment. Despite these issues, Boeing continues to secure significant contracts, indicating continued trust from major industry players.

Portfolio Pulse from Benzinga Neuro

March 06, 2024 | 2:26 pm

BTCUSD

ETHUSD

SPY

Cryptocurrencies including Bitcoin, Ethereum, and Dogecoin face a downturn with $1.15B in potential liquidations. Veteran traders predict a surprise rally for Bitcoin, while Shiba Inu's developer disputes a misquote. Dogecoin's support from Elon Musk keeps it in the spotlight. Ethereum's co-founder sells $100K of ETH amid a dip. US markets show mixed signals with the Fear & Greed Index entering 'Greed' zone and Dow dropping. Nikki Haley's withdrawal from the 2024 Presidential race could favor Trump. US and global politics, economy updates, and tech and EV sector movements, including Tesla's strategies and Rivian's efficiency improvements, are highlighted.

Portfolio Pulse from Akanksha Bakshi

March 06, 2024 | 2:17 pm

DXCM

The FDA has approved DexCom Inc's Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor (CGM) for individuals 18 and older who do not use insulin. The device, which pairs with a smartphone app to display glucose values, will be available online without a prescription starting summer of 2024. This approval could expand access to CGM technology for the 25 million people in the U.S. with Type 2 diabetes who do not use insulin. Following the announcement, DexCom's shares rose by 2.64% in premarket trading.

Portfolio Pulse from Vandana Singh

March 06, 2024 | 2:13 pm

HSCS

HeartSciences has been granted a patent in Canada for its MyoVista Wavelet Technology, a significant development in the company's intellectual property portfolio. This patent enhances HeartSciences' position in the medical technology market, potentially leading to increased market share and revenue through the protection and commercialization of its innovative technology.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:02 pm

CVM

CEL-SCI Corporation (NYSE:CVM) issued a shareholder letter detailing progress on Multikine, a pre-surgical cancer therapy for head and neck cancer. The therapy showed significant survival benefits in a specific patient population, leading to regulatory filings for marketing clearance. CEL-SCI completed its manufacturing facility commissioning and is in discussions with major regulatory bodies including the FDA, EMA, MHRA, and Health Canada. The company plans to seek immediate patient access to Multikine through conditional approvals.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:47 pm

DTIL

Precision BioSciences has announced that its partner, iECURE, received MHRA approval to expand the Phase 1/2 clinical trial of the ARCUS gene editing program for treating OTC deficiency. This development marks a significant step forward in the application of gene editing technologies in addressing genetic disorders.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:45 pm

NVNO

EnVVENO Medical announced positive topline efficacy data from its VenoValve pivotal trial, to be presented at VENOUS2024. The data shows 97% of patients experienced clinical improvement, with 74% showing meaningful benefit. The average improvement was 8 points on the rVCSS, significantly above the threshold for clinical relevance. The company plans to seek FDA approval for VenoValve in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:42 pm

NEPT

Neptune Wellness Solutions Inc. (NASDAQ:NEPT) announced its common shares will be delisted from Nasdaq following a decision by the Nasdaq Hearings Panel. The decision came after Neptune failed to meet the minimum bid price and stockholders' equity requirements for continued listing. Despite an appeal, the Panel upheld the delisting determination. Trading of Neptune's common shares on Nasdaq will be suspended starting March 7, 2024. Neptune is seeking to have its shares quoted on the OTCQB Venture Market.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:42 pm

SPY

Federal Reserve Chairman Jerome Powell indicated that the Fed is on track to cut interest rates this year, citing a notable easing in inflation. However, he emphasized the need for greater confidence in the inflation trajectory before proceeding with rate cuts. Powell also suggested that the current Fed rate is likely at its peak for this cycle, implying that rate cuts could be appropriate later in the year.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:34 pm

CELZ

CRWD

MEDS

CrowdStrike Holdings (CRWD) shares surged 27% after reporting better-than-expected Q4 earnings and revenues, with positive guidance for Q1 and FY25, leading to raised price targets by analysts. Creative Medical Technology Holdings, Inc. (CELZ) saw an 85% increase after receiving FDA Orphan Drug Designation for CELZ-101. TRxADE Health, Inc. (MEDS) announced a special cash dividend of $8/share, resulting in a 67% stock price increase.

Portfolio Pulse from ryanfaloona@benzinga.com

March 06, 2024 | 1:33 pm